Cytokinetics launches Aspen-HCM real-world study evaluating Myqorzo (aficamten) in obstructive HCM
Cytokinetics said it has launched Aspen-HCM, a real-world study evaluating Myqorzo (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Cytokinetics Launches Aspen-Hcm A Real-World Study Evaluating Myqorzo® (Aficamten) In Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated NASDAQ:CYTK
Cytokinetics launches ASPEN-HCM real-world study of MYQORZO (aficamten)
Cytokinetics launched the ASPEN-HCM real-world study evaluating MYQORZO (aficamten) in symptomatic obstructive hypertrophic cardiomyopathy.